861857-83-2Relevant academic research and scientific papers
Design and synthesis of hydroxyethylamine (HEA) BACE-1 inhibitors: Structure-activity relationship of the aryl region
Probst, Gary D.,Bowers, Simeon,Sealy, Jennifer M.,Stupi, Brian,Dressen, Darren,Jagodzinska, Barbara M.,Aquino, Jose,Gailunas, Andrea,Truong, Anh P.,Tso, Luke,Xu, Ying-Zi,Hom, Roy K.,John, Varghese,Tung, Jay S.,Pleiss, Michael A.,Tucker, John A.,Konradi, Andrei W.,Sham, Hing L.,Jagodzinski, Jacek,Toth, Gergely,Brecht, Eric,Yao, Nanhua,Pan, Hu,Lin, May,Artis, Dean R.,Ruslim, Lany,Bova, Michael P.,Sinha, Sukanto,Yednock, Ted A.,Gauby, Shawn,Zmolek, Wes,Quinn, Kevin P.,Sauer, John-Michael
scheme or table, p. 6034 - 6039 (2010/11/04)
The structure-activity relationship of the prime region of hydroxyethylamine BACE inhibitors is described. Variation in the aryl linker region with 5- and 6-membered heterocycles provided compounds such as 33 with improved permeability and reduced P-gp liability compared to benzyl amine analog 1.
METHODS OF TREATMENT OF AMYLOIDOSIS USING ASPARTYL-PROTEASE INHIBITORS
-
Page/Page column 223, (2010/02/13)
The invention relates to acetyl 2-hydroxy-1,3-diaminospirocyclohexanes and derivatives thereof that are useful in treating diseases, disorders, and conditions associated with amyloidosis. Amyloidosis refers to a collection of diseases, disorders, and conditions associated with abnormal deposition of A-beta protein.
